Home
Resources
Publications
Resistance to Bevacizumab in Ovarian Cancer SKOV3 Xenograft Due to EphB4 Overexpression

Resistance to Bevacizumab in Ovarian Cancer SKOV3 Xenograft Due to EphB4 Overexpression

Li Li, Fangfang Nan, Qingzhi Guo, Dongdong Guan, Chao Zhou

J Cancer Res Ther. Oct-Dec 2019;15(6):1282-1287.

PMID: 31898661

Abstract:

Aim of study:
Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined.
Materials and methods:
In this study, we used ovarian xenograft model to evaluate the underlying resistance mechanisms of BV in ovarian cancer treatment.
Results:
Our results showed that EphB4 was overexpressed in BV-resistant xenograft models instead of other common receptor tyrosine kinases. In addition, when coadministrated with EphB4 blocker NVP-BHG712, the antitumor effect of BV was significantly enhanced in the resistant model, further confirmed the role of EphB4 in BV-resistant ovarian cancer. These results indicate that NVP-BHG712 reverses EphB4 overexpression-mediated resistance to BV.
Conclusion:
These findings represent a guide for the design of future medication strategy and may be useful in guiding the use of BV in combination with NVP-BHG712 in patients with resistance or intolerance ovarian cancer.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP940310850	NVP-BHG712		940310-85-0	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: